公开(公告)号：CA3104023A1

公开(公告)日：2019-11-14

申请号：CA3104023

申请日：2019-05-08

Applicant: GENOME AND COMPANY

Inventor： PARK HANSOO ,  PARK SHINYOUNG ,  LEE EUN JU ,  YEON JAE-SUNG ,  JEON HYE HEE ,  KIM WONDUCK ,  CHUNG JOO-YEON ,  JEONG AREUM ,  HOUH YOUN KYUNG ,  SOHN JINYOUNG ,  KIM YUN YEON ,  KIM SANG GYUN ,  LEE SURO

IPC: C12N1/20 ,  A23K10/16 ,  A23L33/135 ,  A61K35/744 ,  A61P35/00

Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.

公开(公告)号：CA3099906A1

公开(公告)日：2019-11-14

申请号：CA3099906

申请日：2019-05-08

Applicant: GENOME AND COMPANY

Inventor： PARK HANSOO ,  PARK SHINYOUNG ,  LEE EUN JU ,  YEON JAE-SUNG ,  JEON HYE HEE ,  KIM WONDUCK ,  CHUNG JOO-YEON ,  JEONG AREUM ,  HOUH YOUN KYUNG ,  SOHN JINYOUNG ,  KIM YUN YEON ,  KIM SANG GYUN ,  LEE SURO

IPC: C12N1/20 ,  A23K10/16 ,  A23L33/135 ,  A61K35/745 ,  A61K35/747 ,  A61P35/00

Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention exhibits effects of inhibiting cancer cell proliferation, decreasing cancer cell motility, suppressing angiogenesis, and increasing anticancer immune responses as well as downregulating the expression of inflammatory factors, thereby preventing or treating cancer or inflammatory diseases. In addition, when used in combination with a chemotherapeutic agent or immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. Further, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits the effect of directly inhibiting cancer cell proliferation and enhancing immunity, thereby preventing or treating cancer. Particularly, the strain has an excellent anticancer effect by secreting metabolites having inhibitory activity against cancer while being established in the gut. In addition, when used in combination with a chemotherapeutic agent or an immunotherapeutic agent, the Lactococcus lactis GEN3033 of the present invention exhibits a better anticancer effect.

公开(公告)号：AU2020277103A1

公开(公告)日：2020-12-17

申请号：AU2020277103

申请日：2020-11-23

Applicant: GENOME AND COMPANY

Inventor： PARK HANSOO ,  PARK SHINYOUNG ,  LEE EUN JU ,  YEON JAE-SUNG ,  JEON HYE-HEE ,  KIM WONDUCK ,  CHUNG JOO-YEON ,  JEONG AREUM ,  HOUH YOUN KYUNG ,  SOHN JINYOUNG ,  KIM YUN YEON ,  KIM SANG GYUN ,  LEE SURO

IPC: C12N1/20 ,  A23K10/16 ,  A23L33/135 ,  A61K35/745 ,  A61K35/747 ,  A61P35/00 ,  C12R1/46

Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect. ma: Porphyromonadacea b: Prevotellaceae mc: Rikenellaceae Md: Enterococcaceae Me Lactbacillaceae Mf: Leuconostocaceae m :Streptococcaceae mh: unclassified SMi: Lactobacillales mj: Bacilli mk: Clostridiaceae -I: Lachnospiraceae i mRuminococcaceae M n: unclassified Smo Clostridiales - o pClostridia - Mq: Erysipelotrichaceac M r: Erysipelotrichales M s: Erysipelotrichi Mt Comnanonadaceae mu: Burkholderiales M v: Betaproteobacteria \, Mw: Enterobacteriaceae M x: Enterobacteriales my: Gammaproteobacteria M z: Verrucomicrobiaceae Ma: Verrucomicrobiales Mal: Verrucomicrobiae Faecalbacterium_prausnitzu Prevotellacopr Coprococcus unclassified Blautia unclassified Bacteroidesplebeius SMB53_unclassified Lachrnospiraceae_unclassified Megamonasunclassified Bifidobacteriumunclassified Lactobacillales_unclassified Bacteroides_caccae Lactobacillus unclassified Bacteroides uniformis Oscillospiraunclassified Bacteroidesovatus Lactobacillus salivarius Weissellaunclassified Parabacteroidesunclassified Escherichia_coli Bacteroidesfragilis Streptococcus_unclassified Klebsiella_unclassified Akkermansia: muciniphila Clostridiales-unclassified Enterococcus unclassified -4 -2 0 2 4 LDA SCORE (log 10) Lung cancer patients - Normal controls